Nicotinamide Mononucleotide (NMN) Benefits: What Studies Report

What NMN is and why researchers study it

Nicotinamide mononucleotide (NMN) is an intermediate in the biosynthesis of nicotinamide adenine dinucleotide (NAD+), a coenzyme used in redox reactions and consumed by enzymes such as sirtuins and PARPs. Reviews of NAD+ metabolism described tissue NAD+ availability as declining in several aging models and outlined the rationale for supplying precursors such as NMN and nicotinamide riboside to raise NAD+ turnover, while also detailing the pharmacological and regulatory challenges of targeting this pathway in people (PMID 39026037). A companion overview of NAD+ boosting strategies similarly catalogued precursor routes, salvage pathway biology and the open questions about which tissues actually take up which precursors (PMID 39693020).

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision, supplement or medication. Nothing below is a recommendation, and no outcome described here should be read as an expected result.

How the evidence is labelled here

Each section states the study type (randomized human trial, review, animal study, cell or tissue study), the population studied, and the direction of effect that researchers reported. Where a commonly discussed benefit has little or no human evidence, that is stated plainly rather than filled in with mechanism.

NAD+ levels: the most consistently reported human finding

The outcome human studies measured most often was NAD+ itself. A randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent trial in healthy middle-aged adults administered NMN once daily for 60 days and reported dose-dependent increases in blood NAD concentrations across the 300 mg, 600 mg and 900 mg groups (PMID 36482258). A 2023 update reviewing the safety and antiaging effects of NMN in human clinical trials described comparable increases in NAD+ or its metabolites across the small trials published to that point, while noting wide variation in dose, duration, assay methods and study populations (PMID 37619764).

Researchers writing on dietary supplementation with NAD+-boosting compounds in humans emphasised that a rise in circulating NAD+ is a biomarker, not a clinical outcome, and that translating blood measurements into tissue-level or functional benefit remained an unresolved question (PMID 37068054). The review on targeting NAD+ metabolism made a related point: precursor uptake, transport and degradation differ by tissue, so plasma changes may not reflect muscle, brain or heart NAD+ status (PMID 39026037).

Metabolic outcomes and insulin sensitivity

The most cited human metabolic result came from a randomized, placebo-controlled trial in postmenopausal women with prediabetes who were overweight or obese; the study administered 250 mg of NMN daily for 10 weeks and reported increased muscle insulin sensitivity together with changes in muscle insulin signaling and remodeling, without reported effects on body composition or other measured metabolic outcomes (PMID 33888596). The trial was small and confined to one population, and its authors framed muscle insulin sensitivity as the primary endpoint rather than a general metabolic benefit (PMID 33888596).

A 2024 overview of human trials testing candidate anti-aging medicines placed results of this kind in context, describing a field built largely on short trials with surrogate endpoints and small sample sizes rather than hard clinical outcomes (PMID 38181790). Whether comparable metabolic changes occur in men, in younger adults, or in people without prediabetes has not been resolved by the trials summarised in the 2023 NMN safety and antiaging update (PMID 37619764).

Physical performance and self-reported health

In the dose-dependent trial of healthy middle-aged adults, researchers reported improvements in six-minute walking test performance and in health questionnaire scores in the higher-dose groups relative to placebo over the 60-day period (PMID 36482258). Those endpoints are functional but subjective or effort-dependent, and the 2023 review of human NMN trials characterised such performance and well-being findings as preliminary, drawn from short studies with limited replication (PMID 37619764). The review of NAD+-boosting supplementation in humans likewise concluded that functional benefit in healthy adults had not been consistently demonstrated across independent trials (PMID 37068054).

Cardiovascular outcomes: mostly preclinical

A 2021 review of NAD+ metabolism in cardiac health, aging and disease summarised the experimental literature linking NAD+ decline to cardiac aging, heart failure models and metabolic remodeling of the myocardium, and described NAD+ precursor repletion as a strategy tested predominantly in animal and cell systems rather than in adequately powered cardiovascular outcome trials (PMID 34843394). No human cardiovascular endpoint trial of NMN appears among the studies summarised in the 2024 review of anti-aging medicine trials (PMID 38181790), so cardiovascular claims rest on mechanism and animal data at present.

Reproductive aging and oocyte quality: animal evidence

Two 2020 mouse studies are the basis for most fertility-related discussion of NMN. One reported that NMN supplementation reversed aspects of the declining quality of maternally aged oocytes, including measures of meiotic competence and mitochondrial function (PMID 32755581). A second reported that NAD+ repletion rescued measures of female fertility during reproductive aging in mice, with improvements in oocyte quality and reproductive output (PMID 32049001). Both are animal studies. Neither tested human fertility outcomes, and extrapolation from mouse ovarian aging to human reproductive medicine is not supported by the human trial literature summarised in the 2023 NMN clinical update (PMID 37619764).

Related preclinical work on the NAD+ biosynthesis enzyme NAMPT examined a Nampt/SIRT2/LDHA pathway and lactate production in follicular dysplasia in polycystic ovary syndrome models, which is mechanistic research on NAD+ metabolism rather than a test of NMN supplementation in patients (PMID 39489197).

Immune aging and cancer immunology: early-stage research

A 2025 translational study reported that interferon-induced senescent CD8+ T cells reduced the efficacy of anti-PD1 immunotherapy in early triple-negative breast cancer models, work that sits within the broader research programme on senescence and immune-cell metabolism (PMID 40929245). This is preclinical and translational oncology research; it does not establish that NMN supplementation alters immune function or cancer outcomes in people, and no such trial is described in the 2024 review of human anti-aging trials (PMID 38181790).

Claimed benefits with weak or absent human evidence

Several benefits commonly attributed to NMN are not supported by published human outcome data:

• Lifespan or "reversing aging": researchers reviewing human trials of candidate anti-aging medicines reported no trial demonstrating an effect on human lifespan, and described biological-age and biomarker endpoints as unvalidated surrogates (PMID 38181790).
• Sleep, fatigue and energy: the 2023 update on NMN in human clinical trials described sleep and fatigue outcomes as inconsistently measured across small studies rather than established findings (PMID 37619764).
• Cognition and neuroprotection: the review of NAD+-boosting compounds in humans identified cognitive endpoints as an area where human data remained limited and future trials were needed (PMID 37068054).
• Skin, hair and appearance: no controlled human skin or hair outcome trial of NMN is summarised in the 2023 NMN clinical update (PMID 37619764).
• Tissue-specific NAD+ restoration: the 2024 NAD+ metabolism review noted that whether oral precursors meaningfully raise NAD+ in target tissues remains an open methodological question (PMID 39026037).

Adverse Events Reported in NMN Trials: What Studies Report

In the randomized, dose-dependent trial of healthy middle-aged adults, researchers reported that NMN at the doses tested over 60 days was well tolerated with no serious adverse events attributed to the supplement (PMID 36482258). The 2023 review focused specifically on the safety and antiaging effects of NMN in human clinical trials concluded that short-term administration in the trials reviewed was generally well tolerated, while noting that study durations were short and populations small (PMID 37619764). Researchers reviewing NAD+-boosting supplementation in humans added that long-term safety, interactions and effects in people with chronic disease have not been characterised (PMID 37068054), and the 2024 NAD+ metabolism review discussed theoretical concerns about sustained NAD+ pathway modulation that remain unresolved (PMID 39026037).

Reading NMN benefit claims critically

1. Check the species. Oocyte and fertility findings came from mouse studies (PMID 32049001).
2. Check the endpoint. A rise in blood NAD is a biomarker, not a clinical outcome, as the human NAD+ supplementation review emphasised (PMID 37068054).
3. Check the population. The insulin sensitivity result came specifically from prediabetic postmenopausal women with overweight or obesity (PMID 33888596).
4. Check replication. Reviewers described the human NMN literature as a set of small, short, heterogeneous trials (PMID 37619764).

Related reading

For background on NMN chemistry, NAD+ biology and how the compound is classified, see the NMN overview.

References

• Human trials exploring anti-aging medicines (Cell Metabolism, 2024)
• The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update (Advances in Nutrition, 2023)
• The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial (GeroScience, 2023)
• Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women (Science, 2021)
• NAD(+) Boosting Strategies (Sub-cellular Biochemistry, 2024)
• Regulation of and challenges in targeting NAD(+) metabolism (Nature Reviews Molecular Cell Biology, 2024)
• Nicotinamide Mononucleotide Supplementation Reverses the Declining Quality of Maternally Aged Oocytes (Cell Reports, 2020)
• Interferon-induced senescent CD8(+) T cells reduce anti-PD1 immunotherapy efficacy in early triple-negative breast cancer (Science Translational Medicine, 2025)
• NAD(+) Repletion Rescues Female Fertility during Reproductive Aging (Cell Reports, 2020)
• NAD(+) Metabolism in Cardiac Health, Aging, and Disease (Circulation, 2021)
• Dietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge and Future Directions (Journals of Gerontology Series A, 2023)
• Nampt/SIRT2/LDHA pathway-mediated lactate production regulates follicular dysplasia in polycystic ovary syndrome (Free Radical Biology & Medicine, 2024)